Levodopa in the treatment of parkinson disease - yesterday and today;Lewodopa w leczeniu choroby parkinsona - wczoraj i dziś

Neurologia i Neurochirurgia Polska

Volumn 46, Issue 1, 2012, Pages 63-75

  Sławek, Jarosław ^a,b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Oddzia Neurologii i Oddzial Udarowy Szpitala Specjalistycznego sw Wojciecha w Gdansku   (Poland)

Author keywords

Levodopa; Parkinson disease; Therapy

Indexed keywords

LEVODOPA;

ARTICLE; PARKINSON DISEASE;

EID: 84858978159     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.5114/ninp.2012.27450     Document Type: Review

References (57)

1. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 2008; 23 (supl. 3): S494-S508.
2. Nutt J.G., Woodword W.R., Hammerstadt J.P. i wsp. The onoff phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984; 310: 483-488.
3. Olanow W.C., Stern M.B., Sethi K. The scientific and clinical basis for the treatment of Parkinson's Disease (2009). Neurology 2009; 21 (supl. 4): S1-S136.
4. Nyholm D., Lennernas H., Gomes-Trolin C. i wsp. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002; 25: 89-96.
5. Birkmayer W., Hornykiewicz O. Der L-3,4,-Dioxo phenyloalanin (DOPA) bei der Parkinson-Akinese. Wien Klin Wohenschr 1961; 73: 787-788.
6. Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-379.
7. Cotzias G.C. L-dopa for parkinsonism N Engl J Med 1968; 278: 630.
8. Hauser R.A. Levodopa: past, present and future. Eur Neurol 2009; 62: 1-8.
9. Amrein R. The history of Madopar. Focus on Parkinson's Disease. 2004; 16 (supl. A): A7-A13.
10. Yahr M.D., Duvoison R.C., Schear M.J. i wsp. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21: 343-354.
11. Holloway R.G., Shoulson I., Fahn S. i wsp. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A 4-year randomized, controlled trial. Arch Neurol 2004; 61: 1044-1053.
12. Rascol O., Brooks D.J., Korczyn A.D. i wsp. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 study group. N Engl J Med 2000; 342: 1484-1491.
13. Whone A.L., Watts R.L., Stoessl A.J. i wsp. Slower progression of Parkinson's disease with ropinirole vs levodopa: The REALPET study. Ann Neurol 2003; 54: 93-101.
14. Oertel W.H., Wolters E., Sampaio C. i wsp. Pergolide vs lewo -dope monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2005; 21: 343-353.
15. Fahn S., Oakes D., Shoulson I. i wsp.; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
16. Olanow C.W., Agid Y., Mizuno Y. i wsp. Levodopa in the treat -ment of Parkinson's disease: current controversies. Mov Disord 2004; 19: 997-1005.
17. Han F., Mytilineou C., Cohen G. L-dopa up-regulates glutha -tione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996; 66: 501-510.
18. Katzenschlager R., Head A., Schrag A. i wsp. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474-480.
19. Goetz C.G., Poewe W., Rascol O. i wsp. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001-2004. Mov Disord 2005; 20: 523-539.
20. Block G., Liss C., Reines S. i wsp. Comparison of immediaterelease and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurology 1997; 37: 23-27.
21. Stocchi F., Rascol O., Kieburtz K. i wsp. Initiating levodopa/ carbidopa therapy with and without entacapone in early Parkin -son disease: the STRIDE-PD study. Ann Neurol 2010; 68: 18-27.
22. Shapira A.H., Obeso J. Timing of treatment initiation in Par -kinson's disease: a need for reappraisal? Ann Neurol 2006; 59: 559-562.
23. Marek K., Jennings D. Can we image premotor Parkinson disease? Neurology 2009; 72 (7 Suppl): S21-S26.
24. Huot P., Lévesque M., Morissette M. i wsp. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. J Chem Neuroanat 2008; 35: 77-84.
25. Sossi V., Dinelle K., Topping G.J. i wsp. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. J Neurochem 2009; 109: 85-92.
26. Scherfler C., Khan N.L., Pavese N. i wsp. Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. Mov Disord 2006; 21: 783-788.
27. Bäckman C.M., Shan L., Zhang Y.J. i wsp. Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study. Mol Cell Endocrinol 2006; 252: 160-166.
28. Anderson E., Nutt J. The long-duration response to levodopa: phenomenology, potential mechanism and clinical implications. Parkinsonism Relat Disord 2011; 17: 587-592.
29. Watts R.L. The role of dopamine agonists in early Parkinson's disease. Neurology 1997; 49 (supl. 1): S34-S48.
30. Poewe W., Antonini A., Zijmans J.C.M. i wsp. Levodopa in the treatment of Parkinson's Disease: an old drug still going strong. Clin Interv Aging 2010; 5: 229-238.
31. Hughes A.J., Lees A.J., Stern G. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. Neurology 1991; 41: 1723-1725.
32. Defer G.L., Widner H., Marié R.M. i wsp. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999; 14: 572-584.
33. Horstink M., Tolosa E., Bonuccelli U. i wsp.; European Federation of Neurological Societies; Movement Disorder Society-European Section. Review of the therapeutic mana -gement of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Move -ment Disorder Society - European Section. Part I: early (un -complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170-1185.
34. Koziorowski D., Friedman A. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease. Mov Disord 2007; 22: 1033-1036.
35. Paisán-Ruiz C., Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology 2010; 75: 1653-1655.
36. Bertoni J.M., Arlette J.P., Fernandez H.H. i wsp. Increased melanoma risk in Parkinson disease: a prospective clinico -pathological study. Arch Neurol 2010; 67: 347-352.
37. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-458.
38. Białecka M., Adamiak U., Gawrońska-Szklarz B. Opty mali -zacja leczenia choroby Parkinsona preparatami lewodopy. Neurol Neurochir Pol 2009; 43: 446-459.
39. Rylander D., Parent M., O'Sullivan S.S. i wsp. Maladaptive plasticity of serotonin axon terminals in levodopa induced dyskinesia. Ann Neurol 2010; 68: 619-628.
40. Henry B., Duty S., Goldberg J.A. i wsp. Increased striatal preproenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 2003; 183: 458-468.
41. Horstink M., Tolosa E., Bonuccelli U. i wsp. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society - European Section. Part II: late (complicated) Parkinson's disease. European Federation of Neurological Societies; Movement Disorder Society -European Section. Eur J Neurol 2006; 13: 1186-1202.
42. Sitek E.J., Sołtan W., Wieczorek D. i wsp. Assessing selfawareness of dyskinesias in Parkinson's disease through movie materials. Funct Neurol 2011; 26: 121-126.
43. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
44. Forsaa E.B., Larsen J.P., Wentzel-Larsen T. i wsp. What predicts mortality in Parkinson disease?: a prospective popu -lation-based long-term study. Neurology 2010; 75: 1270-1276.
45. Rajput A.H. Levodopa prolongs life expectancy and is nontoxic to substantia nigra. Parkinsonism Relat Disord 2001; 8: 95-100.
46. Sławek J., Wieczorek D., Derejko M. i wsp. The influence of vascular risk factors and white matter hyperintensities on the degree of cognitive impairment in Parkinson's disease. Neurol Neurochir Pol 2008; 42: 505-512.
47. Sławek J., Wieczorek D., Derejko M. i wsp. Vascular risk factors do not contribute to motor and cognitive impairment in Par -kinson's disease. Parkinsonism Relat Disord 2010; 16: 73-74.
48. Białecka M., Robowski P., Honczarenko K. i wsp. Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease. Neurol Neurochir Pol 2009; 43: 272-278.
49. Klostermann F., Jugel C., Müller T. i wsp. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2011; 119: 369-372.
50. Sławek J., Bogucki A. Levodopa intestinal infusion therapy in Parkinson's disease. Neurol Neurochir Pol 2010; 44: 396-403.
51. Nyholm D., Nilsson Remahl A.I., Dizdar N. i wsp. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-223.
52. Stocchi F., Fabbri L., Vecsei L. i wsp. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007; 30: 18-24.
53. Stocchi F., Zappia M., Dall'Armi V. i wsp. Mele vodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Mov Disord 2010; 25: 1881-1887.
54. Fox S., Katzenschlager R., Shen-Yang L. i wsp. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (supl. S3): S2-S41.
55. Brime B., Ballesteros M.P., Frutos P. Preparation and in vitro characterization of gelatin microspheres containing levodopa for nasal administration. J Microencapsul 2000; 17: 777-784.
56. Babita K., Tiwary A.K. Transcutaneous delivery of levodopa: enhancement by fatty acid synthesis inhibition. Mol Pharm 2005; 2: 57-63.
57. Forsayeth J., Bankiewicz K.S., Aminoff M.J. Gene therapy for Parkinson's disease: where are we now and where are we going? Expert Rev Neurother 2010; 10: 1839-1844.